Immunology, genetics and microbiota in the COPD pathophysiology: Potential scope for patient stratification

Expert Review of Respiratory Medicine

Volumn 9, Issue 2, 2015, Pages 153-159

  Malhotra, Rajneesh ^a   Olsson, Henric ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

chronic obstructive pulmonary disease; epigenetics; genetics; immunology; microbiota

Indexed keywords

AUTOANTIGEN;

ADAPTIVE IMMUNITY; AUTOIMMUNITY; B LYMPHOCYTE; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; ENVIRONMENTAL FACTOR; EPIGENETICS; FAM13A GENE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; HHIP GENE; HUMAN; IMMUNOLOGY; IMMUNOREGULATION; INNATE IMMUNITY; LUNG MICROFLORA; MICROFLORA; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SMOKING; SMOKING CESSATION; TH1 CELL; ADVERSE EFFECTS; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENOTYPE ENVIRONMENT INTERACTION; HEALTH STATUS; HOST PATHOGEN INTERACTION; LUNG; MICROBIOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

ADAPTIVE IMMUNITY; EPIGENESIS, GENETIC; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; HEALTH STATUS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; LUNG; MICROBIOTA; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SMOKING;

EID: 84924933931     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2015.1000865     Document Type: Review

References (51)

1. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000;343:269-80
2. Silverman EK. Progress in chronic obstructive pulmonary disease genetics. Proc Am Thorac Soc 2006;3:405-8
3. Atamas SP, Chapoval SP, Keegan AD. Cytokines in chronic respiratory diseases. F1000 Biol Rep 2013;5:3-10
4. Pillai SG, Ge D, Zhu G, et al. ICGN Investigators. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet 2009;5: e1000421
5. El-Zein RA, Young RP, Hopkins RJ, Etzel CJ. Genetic predisposition to chronic obstructive pulmonary disease and/or lung cancer: important considerations when evaluating risk. Cancer Prev Res (Phila) 2012;5(4):522-7
6. Bierut LJ, Stitzel JA, Wang JC, et al. Variants in nicotinic receptors and risk for nicotine dependence. Am J Psychiatry 2008;165:1163-71
7. Ware JJ, van den Bree M, Munafò MR. From men to mice: CHRNA5/CHRNA3, smoking behavior and disease. Nicotine Tob Res 2012;14:1291-9
8. DeMeo DL, Mariani T, Bhattacharya S, et al. Integration of genomic and genetic approaches implicates IREB2 as a COPD susceptibility gene. Am J Hum Genet 2009; 85(4):493-502
9. Siedlinski M, Tingley D, Lipman PJ, et al. COPDGene and ECLIPSE Investigators. Dissecting direct and indirect genetic effects on chronic obstructive pulmonary disease (COPD) susceptibility. Hum Genet 2013; 132(4):431-41
10. Ghio AJ, Hilborn ED, Stonehuerner JG, et al. Particulate matter in cigarette smoke alters iron homeostasis to produce a biological effect. Am J Respir Crit Care Med 2008;178:1130-8
11. Ghio AJ, Cohen MD. Disruption of iron homeostasis as a mechanism of biologic effect by ambient air pollution particles. Inhal Toxicol 2005;17(13):709-16
12. Jomova K, Valko M. Importance of iron chelation in free radical-induced oxidative stress and human disease. Curr Pharm Des 2011;17(31):3460-73
13. Ong ST, Ho JZ, Ho B, Ding JL. Iron-withholding strategy in innate immunity. Immunobiology 2006;211(4): 295-314
14. Schaible UE, Kaufmann SH. Iron and microbial infection. Nat Rev Microbiol 2004;2(12):946-53
15. Harrison A, Santana EA, Szelestey BR, et al. Ferric uptake regulator and its role in the pathogenesis of nontypeable Haemophilus influenzae. Infect Immun 2013;81(4): 1221-33
16. Konings AF, Martin LW, Sharples KJ, et al. Pseudomonas aeruginosa uses multiple pathways to acquire iron during chronic infection in cystic fibrosis lungs. Infect Immun 2013;81(8):2697-704
17. Buhnik-Rosenblau K, Moshe-Belizowski S, Danin-Poleg Y, Meyron-Holtz EG. Genetic modification of iron metabolism in mice affects the gut microbiota. Biometals 2012; 25(5):883-92
18. Wilk JB, Chen TH, Gottlieb DJ, et al. A genome-wide association study of pulmonary function measures in the Framingham Heart Study. PLoS Genet 2009;5(3):1170-3
19. Pillai SG, Ge D, Zhu G, et al. ICGN Investigators. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet 2009;5(3): 1498-505
20. Cho MH, Boutaoui N, Klanderman BJ, et al. Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nat Genet 2010;42:200-2
21. Zhou X, Qiu W, Sathirapongsasuti JF, et al. Gene expression analysis uncovers novel hedgehog interacting protein (HHIP) effects in human bronchial epithelial cells. Genomics 2013;101(5):263-72
22. Steiling K, van den Berge M, Hijazi K, et al. A dynamic bronchial airway gene expression signature of chronic obstructive pulmonary disease and lung function impairment. Am J Respir Crit Care Med 2013;187(9):933-42
23. Arrowsmith CH, Bountra C, Fish PV, et al. Epigenetic protein families: A new frontier for drug discovery. Nat Rev Drug Discov 2012;11:384-400
24. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005;352:1967-76
25. Chen ZH, Kim HP, Sciurba FC, et al. Egr-1 regulates autophagy in cigarette smoke-induced chronic obstructive pulmonary disease. PLoS One 2009;3:e3316
26. Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 2005;25:552-63
27. Barnes PJ. Reduced histone deacetylase in COPD: clinical implications. Chest 2006;129:151-5
28. Barnes PJ. Targeting the epigenome in the treatment of asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009;6:693-6
29. Schamberger AC, Mise N, Meiners S, Eickelberg O. Epigenetic mechanisms in COPD: implications for pathogenesis and drug discovery. Expert Opin Drug Discov 2014;9(6):609-28
30. Qiu W, Baccarelli A, Carey VJ, et al. Variable DNA methylation is associated with chronic obstructive pulmonary disease and lung function. Am J Respir Crit Care Med 2012;185(4):373-81
31. DeMeo DL, Silverman EK. Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax 2014;59:259-64
32. Ezzie ME, Crawford M, Cho JH, et al. Gene expression networks in COPD: microRNA and mRNA regulation. Thorax 2012;67:122-31
33. Christenson SA, Brandsma CA, Campbell JD, et al. miR-638 regulates gene expression networks associated with emphysematous lung destruction. Genome Med 2013;5:114
34. Desai H, Eschberger K, Wrona C, et al. Bacterial colonization increases daily symptoms in patients with chronic obstructive pulmonary disease. Ann Am Thorac Soc 2014;11(3):303-9
35. Pragman AA, Kim HB, Reilly CS, et al. The lung microbiome in moderate and severe chronic obstructive pulmonary disease. PLoS One 2012;7(10):e47305
36. Sze MA, Dimitriu PA, Hayashi S, et al. The lung tissue microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;185:1073-80
37. Erb-Downward JR, Thompson DL, Han MK, et al. Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS One 2011;6(2):e16384
38. Larsen JM, Steen-Jensen DB, Laursen JM, et al. Divergent pro-inflammatory profile of human dendritic cells in response to commensal and pathogenic bacteria associated with the airway microbiota. PLoS One 2012;7(2):e31976
39. Marcuzzi A, Bianco AM, Girardelli M, et al. Genetic and functional profiling of Crohn's disease: Autophagy mechanism and susceptibility to infectious diseases. Biomed Res Int 2013;2013:297501
40. Maneechotesuwan K, Kasetsinsombat K, Wamanuttajinda V, et al. Statins enhance the effects of corticosteroids on the balance between regulatory T cells and Th17 cells. Clin Exp Allergy 2013;43(2):212-22
41. Maneechotesuwan K, Kasetsinsombat K, Wongkajornsilp A, Barnes PJ. Decreased indoleamine 2,3-dioxygenase activity and IL-10/IL-17A ratio in patients with COPD. Thorax 2013;68(4):330-7
42. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011; 378(9795):1015-26
43. Barcelo B, Pons J, Ferrer JM, et al. Phenotypic characterisation of T-lymphocytes in COPD: Abnormal CD4+ CD25+ regulatory T lymphocyte response to tobacco smoking. Eur Respir J 2008;31: 555-62
44. Lee SH, Goswami S, Grudo A, et al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 2007;13:567-9
45. Isajevs S, Taivans I, Strazda G, et al. Decreased FOXP3 expression in small airways of smokers with COPD. Eur Respir J 2009;33(1):61-7
46. Packard TA, Li QZ, Cosgrove GP, et al. COPD is associated with production of autoantibodies to a broad spectrum of self-antigens, correlative with disease phenotype. Immunol Res 2013;55(1-3): 48-57
47. Núnez B, Sauleda J, Anto JM, et al. PAC-COPD Investigators. Anti-tissue antibodies are related to lung function in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011;183(8):1025-31
48. Kheradmand F, Shan M, Xu C, Corry DB. Autoimmunity in chronic obstructive pulmonary disease: clinical and experimental evidence. Expert Rev Clin Immunol 2012; 8(3):285-92
49. Prinjha RK, Witherington J, Lee K. Place your BETs: the therapeutic potential of bromodomains. Trends Pharmacol Sci 2012;33(3):146-53
50. Warburton D, Shi W, Xu B. TGF-b-Smad3 signaling in emphysema and pulmonary fibrosis: An epigenetic aberration of normal development. Am J Physiol Lung Cell Mol Physiol 2013;304:L83-5
51. Barrero CA, Perez-Leal O, Aksoy M, et al. Histone 3.3 participates in a self-sustaining cascade of apoptosis that contributes to the progression of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;188:673-83